HYDERABAD: India’s leading pharmaceutical company Hetero, here on Monday, announced the acquisition of a brownfield manufacturing plant at Penjerla in Telangana. The facility spread across 55.27 acres, will be Hetero’s flagship sterile pharmaceutical and biologics manufacturing unit, bolstered by state-of-the-art technology.
The acquisition reinforces Hetero’s renewed commitment to expand its reach and capabilities in order to respond with agility to the world’s evolving health needs and produce high-quality and affordable medicines.
Dr. Vamsi Krishna Bandi, Managing Director, Hetero, said: “We are committed to an investment upwards of US$75 million, (approximately INR 600 Cr) to upgrade and enhance existing facilities at the site andexpand manufacturingof our global biologics and sterile pharmaceutical products.”
With this facility, Hetero aims to add 2000 new jobs in biochemistry, pharmaceutical sciences, molecular biosciences, engineering, and ancillary services.
